Enhancing cancer treatment with engineered T-cells from healthy donors
Improving the Efficacy of Allogeneic Cell Therapies of Cancer
This study is working on a new kind of T-cell therapy for cancer that can be made from healthy donors, so it’s ready to use right away and won’t be rejected by your body, making it more effective for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10894205 on NIH RePORTER |
What this research studies
This research aims to improve the effectiveness of CAR T-cell therapies for cancer by developing a new type of T-cell that can be readily available from healthy donors. The approach focuses on creating 'off-the-shelf' T-cells that are engineered to resist rejection by the patient's immune system, allowing for better persistence and anti-tumor activity. The researchers are optimizing these engineered T-cells for clinical use and plan to initiate a Phase I clinical trial to test their safety and efficacy in patients with various cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced hematological malignancies or solid tumors who may benefit from CAR T-cell therapy.
Not a fit: Patients who have previously received CAR T-cell therapy or those with certain types of cancers that are not responsive to T-cell therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more accessible and effective cancer treatment option for patients through ready-to-use T-cell therapies.
How similar studies have performed: Other research has shown promise in using engineered T-cells for cancer treatment, but this specific approach of using off-the-shelf T-cells is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mo, Feiyan — University of Pennsylvania
- Study coordinator: Mo, Feiyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.